Technology area: Biotechnology & Pharmaceuticals
19 pending office actions • 10 art units • 16 examiners • 0 of 19 (0%) have an AI response strategy ready
Figene LLC has 20 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 17 distinct examiners and 11 distinct art units. KELLY, ROBERT M is the busiest examiner, with 3 pending matters, showing both broad distribution and a recurring examiner relationship.
This is a substantial coordination record for prosecution management. Counsel should maintain a portfolio-level matrix for claim terminology, technical disclosures, cited references, and examiner positions, while preserving application-specific response strategies. The number of pending actions exceeds both the examiner and art-unit counts, so some examination channels cover multiple matters. The 3 matters before KELLY, ROBERT M warrant coordinated review, but each response must remain tied to its own record.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (11%) |
| §102 only | 2 (11%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 2 (11%) |
| Multi-statute (no §101) | 11 (58%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 3 | 74.1% | +24.1% |
| LEVIN, JOEL D | 2 | 58.1% | +35.2% |
| CHEN, CATHERYNE | 1 | 37.5% | +17.9% |
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
| LEONARD, ARTHUR S | 1 | 50.5% | +50.4% |
| FOX, ALLISON M | 1 | 71.0% | +35.7% |
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
| SHEN, WU CHENG WINSTON | 1 | 23.4% | +25.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17310051 | FIBROBLASTS AND MICROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER IMMUNOTHERAPY | DHAR, MATASHA | 86d overdue |
| 17251587 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | REGLAS, GILLIAN CHELSEA | 27d |
| 18042323 | DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS | LEVIN, JOEL D | 34d |
| 17999583 | FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS | FOX, ALLISON M | 42d |
| 17996033 | TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION | ZHU, JIANJIAN | 54d |
| 17997674 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | PALENIK, JEFFREY T | 72d |
| 17755278 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | CHATTIN, AMY MARIE | 72d |
| 18659833 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | KELLY, ROBERT M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18486731 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | LEONARD, ARTHUR S | 18d overdue |
| 18042323 | DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS | LEVIN, JOEL D | 34d |
| 17999583 | FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS | FOX, ALLISON M | 42d |
| 17996033 | TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION | ZHU, JIANJIAN | 54d |
| 18615328 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | CHEN, CATHERYNE | 70d |
| 17997674 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | PALENIK, JEFFREY T | 72d |
| 18659833 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | KELLY, ROBERT M | — |
| 18659876 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | KELLY, ROBERT M | — |
| Art Unit | Apps |
|---|---|
| 1631 | 4 |
| 1638 | 3 |
| 1633 | 3 |
| 1644 | 2 |
| 1632 | 2 |
| 1655 | 1 |
| 1615 | 1 |
| 1682 | 1 |
| 1619 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18659833 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | KELLY, ROBERT M | 1638 | §102§112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18659876 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | KELLY, ROBERT M | 1638 | §102§112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18615328 | STIMULATION OF ANGIOGENESIS BY FIBROBLAST DERIVED EXOSOMES | CHEN, CATHERYNE | 1655 | Other | Non-Final OA | 70d | Pending | Mar 25, 2024 |
| 18603451 | AUGMENTATION OF FIBROBLAST REGENERATIVE ACTIVITY | BELYAVSKYI, MICHAIL A | 1644 | §102DP | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18486731 | GENE THERAPY FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | LEONARD, ARTHUR S | 1631 | §102§103§112DP | Final Rejection | 18d overdue | Pending | Oct 13, 2023 |
| 18042323 | DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS | LEVIN, JOEL D | 1633 | §102§103 | Non-Final OA | 34d | Pending | Feb 21, 2023 |
| 17999583 | FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS | FOX, ALLISON M | 1633 | §102§103Other | Non-Final OA | 42d | Pending | Nov 22, 2022 |
| 17997674 | REDUCTION OF CYTOKINE STORM AND PATHOLOGICAL INFLAMMATION INCLUDING CAUSED BY CORONAVIRUS USING SPHAGNUM AND EXTRACTS THEREOF | PALENIK, JEFFREY T | 1615 | §102§103 | Final Rejection | 72d | Pending | Nov 01, 2022 |
| 17996033 | TREATMENT OF ERECTILE DYSFUNCTION BY FIBROBLAST ADMINISTRATION | ZHU, JIANJIAN | 1631 | §103§112Other | Non-Final OA | 54d | Pending | Oct 12, 2022 |
| 17995609 | IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | HUMPHRIES, NICHOLAS ADAM | 1631 | §103Other | Final Rejection | — | Pending | Oct 06, 2022 |
| 17904180 | TELOMERE LENGTH MODULATION USING FIBROBLASTS | SHEN, WU CHENG WINSTON | 1682 | §102§103§112 | Final Rejection | — | Pending | Aug 12, 2022 |
| 17757383 | SUPPRESSION OF INTERLEUKIN-17 PRODUCTION AND INHIBITION OF TH17 CELL GENERATION BY FIBROBLASTS AND PRODUCTS THEREOF | JOHANSEN, PETER N. | 1644 | §112 | Final Rejection | — | Pending | Jun 15, 2022 |
| 17757314 | AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Non-Final OA | — | Pending | Jun 14, 2022 |
| 17755278 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | CHATTIN, AMY MARIE | 1643 | §102§103§112 | Final Rejection | 72d | Pending | Apr 26, 2022 |
| 17754106 | CANNABIDIOL ADJUVANT THERAPY FOR TREATMENT OF DISC DEGENERATIVE DISEASE | SCHUBERG, LAURA J | 1631 | §103Other | Final Rejection | — | Pending | Mar 24, 2022 |
| 17310051 | FIBROBLASTS AND MICROVESICLES THEREOF FOR REDUCTION OF TOXICITY ASSOCIATED WITH CANCER IMMUNOTHERAPY | DHAR, MATASHA | 1632 | §103§112 | Final Rejection | 86d overdue | Pending | Jul 13, 2021 |
| 17271529 | CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR TREATMENT OF CANCER | LEVIN, JOEL D | 1633 | §102 | Final Rejection | — | Pending | Feb 25, 2021 |
| 17251587 | USE OF FIBROBLASTS AND/OR MODIFIED FIBROBLASTS FOR THREE DIMENSIONAL TISSUE PRINTING | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Non-Final OA | 27d | Pending | Dec 11, 2020 |
| 17052830 | FIBROBLAST DELIVERY OF TUMOR INHIBITORY AGENTS | KELLY, ROBERT M | 1638 | §102 | Final Rejection | — | Pending | Nov 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFigene LLC has 19 pending office actions as of October 2026, spread across 10 art units and 16 examiners.
Robert M Kelly has the most, with 3 of Figene LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
